Lancet-话题@MedSci

#Lancet#

4376篇内容 | 10330人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1831386, encodeId=bae0183138621, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Diabetes Endocrinol：识别英格兰体重和 BMI 变化高风险的成年人——一项使用电子健康记录的纵向、大规模、基于人群的队列研究, objectType=article, longId=220007, objectId=5b8622000e08, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b8622000e08, replyNumber=0, likeNumber=66, createdTime=2022-02-28, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b8622000e08, moduleTitle=Lancet Diabetes Endocrinol：识别英格兰体重和 BMI 变化高风险的成年人——一项使用电子健康记录的纵向、大规模、基于人群的队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b8622000e08)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831432, encodeId=e671183143215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Haematol：全反式视黄酸加大剂量地塞米松可作为新诊断免疫性血小板减少症患者的一线治疗, objectType=article, longId=293423, objectId=5f6429342357, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f6429342357, replyNumber=0, likeNumber=74, createdTime=2022-02-01, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f6429342357, moduleTitle=Lancet Haematol：全反式视黄酸加大剂量地塞米松可作为新诊断免疫性血小板减少症患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f6429342357)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831187, encodeId=9170183118e09, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：派姆单抗单药治疗BCG-无应答性高危型非肌肉浸润性膀胱癌的疗效, objectType=article, longId=211961, objectId=5b9821196102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b9821196102, replyNumber=0, likeNumber=86, createdTime=2022-01-11, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b9821196102, moduleTitle=Lancet Oncol：派姆单抗单药治疗BCG-无应答性高危型非肌肉浸润性膀胱癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b9821196102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831328, encodeId=8c2218313289b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Haemat：瘤内注射TTI-621治疗复发性或难治性蕈样真菌病或Sézary综合征的安全性, objectType=article, longId=218260, objectId=769721826066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769721826066, replyNumber=0, likeNumber=53, createdTime=2022-07-02, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769721826066, moduleTitle=Lancet Haemat：瘤内注射TTI-621治疗复发性或难治性蕈样真菌病或Sézary综合征的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=769721826066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831297, encodeId=24fd183129efd, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Rheumatology: 托珠单抗单药治疗用于巨细胞动脉炎超短糖皮质激素给药之后：一项单臂、开放标签、概念验证研究, objectType=article, longId=217033, objectId=473221e033ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=473221e033ac, replyNumber=0, likeNumber=59, createdTime=2022-05-18, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=473221e033ac, moduleTitle=Lancet Rheumatology: 托珠单抗单药治疗用于巨细胞动脉炎超短糖皮质激素给药之后：一项单臂、开放标签、概念验证研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=473221e033ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831108, encodeId=d82d18311087d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验, objectType=article, longId=209670, objectId=f8062096e0cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8062096e0cf, replyNumber=0, likeNumber=69, createdTime=2021-09-27, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8062096e0cf, moduleTitle=Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8062096e0cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831123, encodeId=a549183112370, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：支持使用血小板功能或基因检测来优化PCI患者的药物选择, objectType=article, longId=210096, objectId=f8f921009607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8f921009607, replyNumber=0, likeNumber=63, createdTime=2022-01-01, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8f921009607, moduleTitle=Lancet：支持使用血小板功能或基因检测来优化PCI患者的药物选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8f921009607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831159, encodeId=b3f11831159d1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：论护士的重要性！护士每少管1个患者，患者死亡风险降低7%！, objectType=article, longId=211204, objectId=6049211204a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6049211204a2, replyNumber=0, likeNumber=68, createdTime=2021-06-25, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6049211204a2, moduleTitle=Lancet：论护士的重要性！护士每少管1个患者，患者死亡风险降低7%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6049211204a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831272, encodeId=6b7418312e2e5, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet子刊 | 再添证据！减肥“神药”索马鲁特每周一次的更佳剂量来了！, objectType=article, longId=215740, objectId=3737215e4023, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3737215e4023, replyNumber=0, likeNumber=69, createdTime=2021-12-26, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3737215e4023, moduleTitle=Lancet子刊 | 再添证据！减肥“神药”索马鲁特每周一次的更佳剂量来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3737215e4023)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831304, encodeId=a2df1831304d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：只放疗不手术，IA期NSCLC患者的生存预后完全不输肺叶切除+淋巴结清扫！, objectType=article, longId=217218, objectId=98cb21e218a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98cb21e218a9, replyNumber=0, likeNumber=71, createdTime=2022-08-03, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98cb21e218a9, moduleTitle=Lancet Oncol：只放疗不手术，IA期NSCLC患者的生存预后完全不输肺叶切除+淋巴结清扫！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98cb21e218a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831083, encodeId=7ff518310833e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Public Health:妈妈孕前心理社会危险因素影响孩子, objectType=article, longId=208828, objectId=519820882866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=519820882866, replyNumber=0, likeNumber=80, createdTime=2022-02-09, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=519820882866, moduleTitle=Lancet Public Health:妈妈孕前心理社会危险因素影响孩子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=519820882866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831470, encodeId=6a8818314e0f1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌, objectType=article, longId=295669, objectId=d4cf2956690e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4cf2956690e, replyNumber=0, likeNumber=50, createdTime=2022-06-22, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4cf2956690e, moduleTitle=Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4cf2956690e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831460, encodeId=cd071831460d2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：芳香酶抑制剂对比他莫昔芬治疗绝经前的ER阳性早期乳腺癌, objectType=article, longId=295172, objectId=0c822951e291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c822951e291, replyNumber=0, likeNumber=68, createdTime=2022-05-27, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c822951e291, moduleTitle=Lancet Oncol：芳香酶抑制剂对比他莫昔芬治疗绝经前的ER阳性早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c822951e291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831219, encodeId=b254183121991, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！, objectType=article, longId=213129, objectId=c62f21312916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62f21312916, replyNumber=0, likeNumber=71, createdTime=2022-04-16, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62f21312916, moduleTitle=Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62f21312916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831452, encodeId=5ac618314521f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌, objectType=article, longId=294982, objectId=f5d12949827b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d12949827b, replyNumber=0, likeNumber=74, createdTime=2022-03-14, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d12949827b, moduleTitle=Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5d12949827b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831313, encodeId=5bf61831313b1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet子刊：200万人数据提示，18-24岁体重从正常到超重甚至肥胖的风险最高！, objectType=article, longId=217601, objectId=823021e6016d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=823021e6016d, replyNumber=0, likeNumber=69, createdTime=2021-10-28, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=823021e6016d, moduleTitle=Lancet子刊：200万人数据提示，18-24岁体重从正常到超重甚至肥胖的风险最高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=823021e6016d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831346, encodeId=83491831346a1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, objectType=article, longId=219170, objectId=015e2191e0a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015e2191e0a9, replyNumber=0, likeNumber=96, createdTime=2021-11-28, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015e2191e0a9, moduleTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015e2191e0a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831213, encodeId=bd65183121375, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, objectType=article, longId=212817, objectId=1b8121281e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8121281e7b, replyNumber=0, likeNumber=69, createdTime=2021-10-27, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8121281e7b, moduleTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8121281e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831068, encodeId=ae7b1831068c0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：1990-2019全球听力受损患病率研究, objectType=article, longId=208340, objectId=0b6920834062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b6920834062, replyNumber=0, likeNumber=78, createdTime=2021-07-22, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b6920834062, moduleTitle=Lancet：1990-2019全球听力受损患病率研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b6920834062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831103, encodeId=e37118311031e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, objectType=article, longId=209579, objectId=b43d2095e9ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43d2095e9ba, replyNumber=0, likeNumber=143, createdTime=2022-03-13, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43d2095e9ba, moduleTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b43d2095e9ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Lancet

2020-05-29

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Diabetes Endocrinol：识别英格兰体重和 BMI 变化高风险的成年人——一项使用电子健康记录的纵向、大规模、基于人群的队列研究

2022-02-28

zhouqu_8 (审核中...)

前往app查看评论内容

#Lancet#

Lancet Haematol：全反式视黄酸加大剂量地塞米松可作为新诊断免疫性血小板减少症患者的一线治疗

2022-02-01

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：派姆单抗单药治疗BCG-无应答性高危型非肌肉浸润性膀胱癌的疗效

2022-01-11

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Haemat：瘤内注射TTI-621治疗复发性或难治性蕈样真菌病或Sézary综合征的安全性

2022-07-02

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Rheumatology: 托珠单抗单药治疗用于巨细胞动脉炎超短糖皮质激素给药之后：一项单臂、开放标签、概念验证研究

2022-05-18

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验

2021-09-27

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：支持使用血小板功能或基因检测来优化PCI患者的药物选择

2022-01-01

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：论护士的重要性！护士每少管1个患者，患者死亡风险降低7%！

2021-06-25

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet子刊 | 再添证据！减肥“神药”索马鲁特每周一次的更佳剂量来了！

2021-12-26

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：只放疗不手术，IA期NSCLC患者的生存预后完全不输肺叶切除+淋巴结清扫！

2022-08-03

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Public Health:妈妈孕前心理社会危险因素影响孩子

2022-02-09

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：纳武单抗联合奥沙利铂化疗一线治疗晚期或复发性胃或胃食管交界癌

2022-06-22

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：芳香酶抑制剂对比他莫昔芬治疗绝经前的ER阳性早期乳腺癌

2022-05-27

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！

2022-04-16

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌

2022-03-14

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet子刊：200万人数据提示，18-24岁体重从正常到超重甚至肥胖的风险最高！

2021-10-28

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？

2021-11-28

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！

2021-10-27

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：1990-2019全球听力受损患病率研究

2021-07-22

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期

2022-03-13

科室
- - 订阅+
  - 更多科室
工具
服务